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Data resource basics
Why was the resource established?
Colorectal cancer is a major public health problem in the
UK. Each year in the UK around 41 000 people are diag-
nosed with the disease, 16 000 die from it1 and interna-
tional comparisons indicate that survival rates are lower
than those attained by our economic neighbours.2,3 It is es-
timated that detecting and managing the illness costs the
National Health Service (NHS) in excess of £1.1 billion an-
nually.4,5 Despite this outlay, there remain major varia-
tions in diagnosis, treatment and outcomes.6–8 In parallel,
the research community invests significant resource and ef-
fort into understanding the aetiology of the disease and de-
veloping more effective and efficient methods of detecting
and managing it.
High-quality data are essential to improving outcomes.
Good intelligence underpins patient choice, helping indi-
viduals reduce the risk of disease and access the best care.
It identifies and quantifies inequalities, improves the cost-
effectiveness and quality of services and supports cancer
research. Unfortunately, although there are numerous indi-
vidual datasets containing important information about
the disease and its management, both across the UK
nations and internationally, the availability of high-quality
cancer intelligence has been limited due to the challenges
researchers face in gaining access to them.9 The UK
Colorectal Cancer Intelligence Hub has sought to address
these data access challenges by creating a single UK colo-
rectal cancer research data system as a model for
data-driven research into all cancer types. Working in part-
nership with the public, patients, carers, data providers
and data users, we have created a single research reposi-
tory, known as the COloRECTal cancer data Repository
(CORECT-R). This resource is seeking to house all the co-
lorectal cancer data described in Figure 1 and make them
more readily accessible to researchers, while ensuring the
security of the data to protect patient confidentiality. In
this way, the UK Colorectal Cancer Intelligence Hub seeks
to generate the intelligence needed to promote early diag-
nosis, optimize treatment, support clinical research and, ul-
timately, improve the UK’s colorectal cancer outcomes.
At present, the resource contains information on all
individuals diagnosed with colorectal and anal cancer in
England between 1997 and 2018. This includes informa-
tion on more than 600 000 cases of the disease. Much
more remains to be done, however, and by incorporating
more colorectal datasets from across the UK, and
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potentially beyond, the UK Colorectal Cancer Intelligence
Hub aims to provide an annually updated and richer re-
source dedicated to research. This will enable far more per-
tinent analyses than have previously been possible.
The CORECT-R resource, and analyses based upon the
data within it, has received approval from the South West-
Central Bristol research ethics committee (18/SW/0134).
Data collected
In the UK, large population datasets already exist which
contain detailed information on all cancer patients. For ex-
ample, in England the National Cancer Registration and
Analysis Service (NCRAS) curates high-quality national
cancer registration datasets that contain information on ev-
ery tumour diagnosed in the country.10 Via linkage, or po-
tential linkage, of these data to other administrative health
datasets, such as inpatient and outpatient activity
(Hospital Episode Statistics—HES),11 radiotherapy data
(the National Radiotherapy Dataset—RTDS), cancer med-
icines prescribing (the Systemic Anti-Cancer Therapy—
SACT),12 mortality data (Office for National Statistics)
and many other similar datasets, there already exists a rich
linked cancer data resource. Public health organizations
have also built similar high-quality resources in Wales,13
Scotland14 and Northern Ireland.15 What has not hap-
pened routinely, however, is curation of these datasets at a
disease level by academic and disease experts to realize the
full potential of the information within them.
Furthermore, it has often been extremely difficult for such
experts to access the datasets, not least as the data are so
detailed that access must be restricted to protect the confi-
dentiality of the people the data pertain to.16 The
CORECT-R model seeks to address these challenges by en-
abling dedicated data managers to work with the linked
datasets within the secure digital environments, known as
‘Safe Havens’, of the respective jurisdictions.14,15,17,18 In
this setting, the data managers act as colorectal cancer data
experts and focus on the processing and management of
the relevant datasets to enhance their utility and availabil-
ity. This can be by, for example, deriving new variables
from linked datasets and resolving quality assurance prob-
lems such as conflicting versions of the same data item aris-
ing from different data sources. Having dedicated data
managers working within approved secure environments
limits access to the most sensitive data items, by enabling
the production of de-identified ‘research ready’ datasets
for use by the cancer intelligence community.
The types of data hosted and/or linked in CORECT-R
can be categorized into four main groups: routine cancer
datasets, routine non-cancer datasets, consented datasets
and biological samples. These groups will be described
briefly here, but further details of the datasets available
can be found in the CORECT-R data catalogue [https://
www.ndph.ox.ac.uk/corectr/corect-r].
The first group, routine cancer datasets (such as cancer
registry, patient discharge and treatment datasets), are al-
ready held within CORECT-R. These datasets provide
high-quality information on many aspects of the patient
pathway, including initial cancer diagnosis, treatments
Key Features
• CORECT-R provides an extremely secure, but researcher accessible, environment in which datasets relevant to
colorectal cancer in the UK are efficiently linked, curated and analysed. It aims to overcome the significant challenges
and duplication associated with access to administrative datasets and drive the production of intelligence to improve
outcomes from the disease.
• Ethical approval to establish CORECT-R as a research database was obtained in 2018. Currently, the resource
predominantly contains secondary administrative datasets relevant to the English colorectal cancer population.
Expansion to cover the whole of the UK is under way.
• CORECT-R aims to capture detailed diagnostic, management and outcome information about all UK individuals
diagnosed with, or at risk of developing, colorectal cancer. It currently contains wide-ranging information on more
than 600 000 tumours. The confidentiality and security of the data within the resource is paramount and extensive
procedures are in place to protect the information.
• CORECT-R has been developed by the UK Colorectal Cancer Intelligence Hub. Funded by Cancer Research UK, it is a
collaboration between academics, clinical experts, patients and the public. Visit [https://www.ndph.ox.ac.uk/corectr] or
contact [crchub@leeds.ac.uk] to obtain more information on how to access CORECT-R, collaborate with the Hub team
and investigate questions of interest.
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received and subsequent outcomes, and are providing
strong intelligence to inform and improve NHS colorectal
cancer services.7,19–21
The second group CORECT-R hosts is routine adminis-
trative datasets that contain information on people without
a diagnosis of cancer. Examples of such ‘non-cancer’ data
would be information on individuals participating in a
screening programme, who are not identified as having
cancer or prescription information from a population of
people without cancer but who are comparable in terms of
age and sex to those who do.22 These data are important,
as many of the studies using CORECT-R will be strength-
ened by information on a comparable population without
cancer. For example, studies looking to generate evidence
to strengthen diagnostic pathways will require information
on all who undergo the relevant diagnostic tests and not
simply those who go on to get cancer. Similarly, to study
the full impact of colorectal cancer on a population it is im-
portant to make comparisons with those without colorec-
tal cancer. Linkage to non-cancer datasets is, therefore,
essential to gain the intelligence needed to significantly im-
prove colorectal cancer outcomes. The non-cancer datasets
will contain no direct patient identifiers (being incorpo-
rated and linked via a secure pseudonymized process23),
meaning that members of the CORECT-R team and users
of the resource will be unable to ascertain the identity of
those individuals without cancer.
The third group is consented datasets. A huge number
of colorectal cancer research studies are undertaken in
which individuals have consented to participate, including
randomized clinical trials, cohort studies and surveys. Such
studies often capture very detailed data (including study
outcome measures, patient-reported outcomes and genetic
information) that go beyond what is available in routine
datasets, and so their inclusion has the potential to strongly
enhance elements of the data. A specific example of such
data already incorporated into CORECT-R is the patient-
reported outcomes data taken from a national survey of
colorectal cancer patients.24,25 CORECT-R does not al-
ways hold the additional data or samples from these con-
sented studies, but linkage facilitates access to the relevant
components of the CORECT-R data and these associated
studies. Where feasible and the necessary approvals allow,
individuals within CORECT-R who have consented to
such studies are flagged. Over time, linkage to more con-
sented datasets will be facilitated, but this is dependent on
the approvals under which study data were collected.
Finally, CORECT-R also enables linkage to samples.
Access to biological samples increases the scope of colorec-
tal cancer research by enabling phenotype to be related to
management and outcomes. CORECT-R does not host
these samples directly but flags cases where these data are
available. This enables identification of relevant cases and
access for research projects (again, where all relevant ethi-
cal and information governance approvals are in place).
An example of such data is the pathology specimens being
collected through the Yorkshire Cancer Research Bowel
Cancer Improvement Programme, where digital images of
tumour sections are linked to the routine cancer datasets
held in CORECT-R.
Researchers can seek to access all the datasets within
CORECT-R in their standard or linked format. In addition
however, key pieces of information will be extracted from
these component datasets to form national colorectal and
anal cancer datasets. These are intended to be ‘research
ready’, pseudonymized population-based datasets that
researchers can easily access. They avoid the need for users
to independently request broader extracts of data and rep-
licate linkages to obtain commonly used key information
(for example stage at diagnosis, comorbidity scores or
treatment information). These datasets are continually de-
veloping and full details are available on the Hub website
[https://www.ndph.ox.ac.uk/corectr]. Tables 1 and 2 sum-
marize their current content.
Figure 1 Types of data available within CORECT-R.
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Table 1 Variables in the National Colorectal Cancer Dataset within CORECT-R. Currently, these relate to the English population
but work is underway to expand to cover the UK
Data item Description of field content Format Source of information
Pseudonymized person ID Unique study specific identifier for each patient Number Derived by the UK Colorectal Cancer
Intelligence Hub
Pseudonymised tumour ID Unique study specific identifier for each tumour Number Derived by the UK Colorectal Cancer
Intelligence Hub
Age Option to derive age information in a format
suitable for the research project needs. Can be
single age or summarized in age bands (e.g. 5-
year) and can also include month and year of
birth
Number Cancer registration dataset
Sex 0¼not known, 1¼male, 2¼ female, 9¼not
specified
Number Cancer registration dataset
Ethnic group Option to group ethnicities (e.g White/non-
White/unknown). Several methods of deriving
ethnicity information have been used previ-
ously and can be derived as per user
requirements
Text Derived by the UK Colorectal Cancer
Intelligence Hub from information in the
cancer registration and hospital discharge
datasets
Socioeconomic status Option to include an appropriate indicator of so-
cioeconomic status such as the Index of
Multiple Deprivation
Number Derived by the UK Colorectal Cancer
Intelligence Hub from information in mul-
tiple datasets
Vital status of the patient A, alive; D, dead; X, exit posting Char(1) Cancer registration dataset
Days from diagnosis to
death
Time in days between specified colorectal cancer
diagnosis and death or censoring
Number Derived by the UK Colorectal Cancer
Intelligence Hub from information in the
cancer registration dataset
Days from another event to
date of death
Option to provide number of days from another
event to death (e.g. days from diagnosis to
death). Derived as per user requirements
Number Derived by the UK Colorectal Cancer
Intelligence Hub from information in key
events from different datasets
Cause of death Option to derive summary cause of death infor-
mation based on the causes of death listed on
death certificates or coded by former regional
registries. Derived as per user requirements
Text Cancer registration dataset
Place of death Option to derive place of death based on infor-
mation recorded on death certificates or from
Hospital Episode Statistics Derived as per user
requirements
Cancer registration dataset
Diagnosis date Option to derive diagnosis date in a format suit-
able for the research project needs. This is
likely to be in the format MM/YYYY unless
permissions for access to identifiable data have
been granted
Cancer registration dataset
Days from another event to
date to diagnosis
Option to provide number of days from another
event to diagnosis (e.g. days from birth to di-
agnosis). Derived as per user requirements
Number Derived by the UK Colorectal Cancer
Intelligence Hub from information in mul-
tiple datasets
Basis of diagnosis of the
tumour
0¼death certificate, 1¼ clinical diagnosis made
before death without (2-7), 2¼ clinical investi-
gation, 4¼ specific tumour markers,
5¼ cytology, 6¼histology of metastases,
7¼histology of a primary tumour,
9¼unknown
Number Cancer registration dataset
Route to diagnosis 1¼GP referral, 2¼2-week wait pathway, 3¼
emergency presentation, 4¼other outpatient,
5¼ screen detected, 6¼ inpatient elective,
7¼death certificate only, 9¼unknown
Number Cancer registration dataset
(Continued)
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Table 1 Continued
Data item Description of field content Format Source of information
Site of neoplasm (4-charac-
ter code)
Valid 4-digit ICD-10 codes in the range C180 to
C20
Char(4) Cancer registration dataset
Site of neoplasm (3-charac-
ter code)
Valid 3-digit ICD-10 codes in the range C18 to
C20
Char(4) Cancer registration dataset
Site of neoplasm (coded) 1¼ right colon, 2¼ left colon, 3¼ colon, unspe-
cified, 4¼ rectosigmoid, 5¼ rectum
Number Derived by the UK Colorectal Cancer
Intelligence Hub from information in the
cancer registration dataset
Morphology The original 5-digit ICD-03 morphology infor-
mation captured by NCRAS
Char(5) Cancer registration dataset
Morphology group A grouped morphology variable derived by
grouping the detailed morphology information
available in NCRAS to provide the more use-
able histology types of adenocarcinoma etc.
For many analyses it may be appropriate to
limit cases to exclude rare morphological sub-
types with non-standard treatment or unusual
behaviour
Number Derived by the UK Colorectal Cancer
Intelligence Hub from information in the
cancer registration dataset
Summary stage A summary stage, that combines information
from the multiple staging variables available
in NCRAS to maximize the number of cases
with a stage classification
Number Cancer registration dataset
Staging information Option to derive staging information from any
of the data items available in the CORECT-R
tables (likely to be predominantly NCRAS
Tumour table). This can include individual
components of TNM or any other information
that can be reported alone or combined as
demanded by the research project. Derived as
per user requirements
Derived by the UK Colorectal Cancer
Intelligence Hub from information in the
cancer registration dataset
Comorbidity scores Option to access a number of different comor-
bidity scores (such as Charlson, Elixhauser,
C3) created as per user requirements. This
could include using a previously published ap-
plication of these scores or bespoke algorithms
as demanded by the research project
Number Derived by the UK Colorectal Cancer
Intelligence Hub from information in mul-
tiple datasets
Primary procedure Primary procedure for this individual, 1¼major
resection, 2¼minor resection, 3¼bypass,
4¼ stoma, 5¼ stent, 6¼no surgery, 7¼ no
link to HES so no information available
Number Derived by the UK Colorectal Cancer
Intelligence Hub from information in the




The OPCS4 code indicating the exact procedure
determined as the primary event
Char(4) Hospital discharge dataset
Date of primary procedure MM/YYYY Number Hospital discharge dataset
Method of admission to
hospital for primary
procedure
Derived from the HES variable admission
method, 0¼ elective, 1¼ emergency,
99¼unknown
Number Hospital discharge dataset
Location patient admitted
from
1¼Unsupervised accommodation, no care pro-
vided, 2¼hospital, 3¼ supervised accommo-
dation, health care is provided, 4¼ supervised
accommodation, no care provided,
99¼unknown
Number Hospital discharge dataset
Urgency of surgery 0¼ elective 1¼ emergency Number Derived by the UK Colorectal Cancer
Intelligence Hub from information in the
relevant hospital discharge dataset
(Continued)
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Table 1 Continued
Data item Description of field content Format Source of information
Destination patient dis-
charged to after primary
procedure
1¼unsupervised accommodation, no care pro-
vided, 2¼hospital, 3¼ supervised accommo-
dation, health care is provided, 4¼ supervised
accommodation, no care provided, 9¼patient
died, 99¼unknown
Number Hospital discharge dataset
Days between diagnosis
and primary procedure
Option to provide number of days from another
event to diagnosis (e.g. days from birth to di-
agnosis). Derived as per user requirements
Number Derived by the UK Colorectal Cancer
Intelligence Hub from information in the
cancer registry and relevant hospital dis-
charge dataset
Interval between primary
procedure and death or
when censored
Option to provide number of days from another
event to date of death (e.g. days from birth to
diagnosis). Derived as per user requirements
Number Derived by the UK Colorectal Cancer
Intelligence Hub from information in the
cancer registry and relevant hospital dis-
charge dataset
Length of stay in days in
the spell of care associ-
ated with the primary
procedure
Total length of stay in hospital associated with
the primary procedure
Number Derived by the UK Colorectal Cancer
Intelligence Hub from information in the
relevant hospital discharge dataset
Length of postoperative
stay in hospital
Length of post-primary procedure stay in hospi-
tal in days
Number Derived by the UK Colorectal Cancer
Intelligence Hub from information in the
relevant hospital discharge dataset
Emergency readmission
within 30 days of dis-
charge following primary
procedure
0¼no, 1¼ yes Number Derived by the UK Colorectal Cancer
Intelligence Hub from information in the
relevant hospital discharge dataset
Death within 30 days of pri-
mary procedure
0¼ alive 1¼dead Number Derived by the UK Colorectal Cancer
Intelligence Hub from information in the
cancer registry and relevant hospital dis-
charge dataset
Death within 90 days of pri-
mary procedure
0¼ alive, 1¼dead Number Derived by the UK Colorectal Cancer
Intelligence Hub from information in the
cancer registry and relevant hospital dis-
charge dataset
Death during hospital stay
of primary procedure
0¼no 1¼ yes Number Derived by the UK Colorectal Cancer
Intelligence Hub from information in the
relevant hospital discharge dataset
NHS Trust for primary
procedure
Char(5) Derived by the UK Colorectal Cancer
Intelligence Hub from information in the
relevant hospital discharge dataset
Multidisciplinary team for
primary procedure
Char(5) Derived by the UK Colorectal Cancer
Intelligence Hub from information in the
cancer registry and relevant hospital dis-
charge dataset
Stoma opened at major
resection
0¼no, 1¼ yes Number Derived by the UK Colorectal Cancer
Intelligence Hub from information in the
relevant hospital discharge dataset
Stoma still open at
18 months following ma-
jor resection
0¼ closed, 1¼open Number Derived by the UK Colorectal Cancer
Intelligence Hub from information in the




0¼open, 1¼ laparoscopic Number Derived by the UK Colorectal Cancer
Intelligence Hub from information in the
relevant hospital discharge dataset
(Continued)
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Table 1 Continued
Data item Description of field content Format Source of information
Converted laparoscopic
procedures
0¼not converted, 1¼ converted, 9¼not
laparoscopic
Number Derived by the UK Colorectal Cancer
Intelligence Hub from information in the
relevant hospital discharge dataset
Type of laparoscopic
procedure
0¼ standard laparoscopic, 1¼ robotic
laparoscopic
Number Derived by the UK Colorectal Cancer
Intelligence Hub from information in the
relevant hospital discharge dataset
Return to theatre Indicator of whether an individual had an emer-
gency return to theatre following their major
resection within 30 days of surgery
Number Derived by the UK Colorectal Cancer
Intelligence Hub from information in the
relevant hospital discharge dataset
Reason for return to theatre Reason for the return to theatre Derived by the UK Colorectal Cancer
Intelligence Hub from information in the
relevant hospital discharge dataset
Failure to rescue Death within 30 days of the return to theatre Number Derived by the UK Colorectal Cancer
Intelligence Hub from information in the
relevant hospital discharge dataset
Consultant listed as over-
seeing the episode of care








Number Derived by the UK Colorectal Cancer
Intelligence Hub from information in the
relevant hospital discharge dataset
4¼upper gastrointestinal/hepatobiliary/bariatric
5¼ transplant
6¼ general surgery 9¼other/unknown
ACPGBI membership status
of consultant
0¼non-member of the ACPGBI
1¼member of the ACPGBI
Char(1) Derived by the UK Colorectal Cancer
Intelligence Hub from information in the
relevant hospital discharge dataset
Geography of diagnosis Option to provide any geography listed at
LOCATION based on the postcode of resi-
dence of the patient at the time of diagnosis of
the colorectal tumour Derived as per user
requirements
Derived by the UK Colorectal Cancer
Intelligence Hub from information in mul-
tiple datasets
Geography of diagnosis and
treatment
Option to provide any geography listed at
LOCATION based on the hospitals of diagno-
sis and treatment of the patient at any time in
their pathway of care. Derived as per user
requirements
Derived by the UK Colorectal Cancer
Intelligence Hub from information in mul-
tiple datasets
Travel time Option to provide road travel time for each pa-
tient between their home and relevant hospi-
tals they attended at any point across the care
pathway. Derived as per user requirements
Derived by the UK Colorectal Cancer
Intelligence Hub from information in mul-
tiple datasets
Travel distance Option to provide road travel distance for each
patient between their home and relevant hos-
pitals they attended at any point across the
care pathway. Derived as per user
requirements
Derived by the UK Colorectal Cancer





1¼ short course radiotherapy with immediate
surgery
Number Derived by the UK Colorectal Cancer
Intelligence Hub from information in mul-
tiple datasets
2¼ short course radiotherapy with delayed
surgery
3¼ long course chemoradiotherapy
(Continued)
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The CORECT-R system also provides a secure Trusted
Research Environment (TRE) via which researchers can ac-
cess data. The CORECT-R TRE is a secure analytical area
that, following both project and user approval, is accessed
via two-factor authentication and a virtual desktop. It con-
tains database and statistical analysis software and users
can also bring their own software in to the environment
once approved. The TRE infrastructure is provided by the
company AIMES and hosted in partnership with Cancer
Research UK.
Data resource use
The potential of the data in CORECT-R is huge, enabling
research into all aspects of the disease from its aetiology to
its management and outcome. Ethical approval to establish
a Research Database was obtained (UK NHS Health
Research Authority 18/SW/0134) and this supports the use
of its contents for projects that will promote early diagno-
sis, help quantify and address inequalities, support cancer
research and improve outcomes. The Scottish Public
Benefit Privacy Panel has also approved an initial phase of
the Programme (PBPP: 1718–0026), with data accessible
to the current project team. If a researcher has a project be-
yond these approved uses, the Hub will actively support
applications to extend the use of the resource.
An example of how the resource has been used is the in-
vestigation of post-colonoscopy colorectal cancers
(PCCRCs). These can occur when the main diagnostic test
used to identify the disease, colonoscopy, fails to detect the
tumour or the precursor lesion. Via linkage and analysis of
cancer registry, hospital and screening data (combined in
CORECT-R), work has been undertaken to identify
PCCRCs and understand their occurrence across the
English NHS.7,26 These studies have helped to identify
groups of individuals at greater risk of developing a
PCCRC and also colonoscopy providers with significantly
higher, and lower, PCCRC rates.7 To try and ensure this
intelligence is used to inform efforts to reduce rates, the
results of the study were disseminated in the peer-reviewed
literature and to all colonoscopy providers via the Getting
it Right First Time (GIRFT) programme.27 In addition, all
providers with outlying rates, in both a positive and nega-
tive direction, were directly informed of their results. This
led many to seek to review their cases to understand why
they arose. The CORECT-R team supported and facili-
tated their applications to the Office for Data Release at
Public Health England to identify their PCCRC cases and
to audit their colonoscopy services.
The resource is routinely used to quantify variations in
colorectal cancer care across the NHS. For example, the
Yorkshire Cancer Research Bowel Cancer Improvement
Programme28 has used the data to produce annual reports
quantifying variation in the patient (sex, age, socioeco-
nomic status and comorbidity) and tumour (stage at diag-
nosis, site of tumour and mode of presentation)
characteristics of the colorectal cancer populations treated
by each of Yorkshire’s multidisciplinary teams, as well as
variation in management and outcome. Treatments exam-
ined include use and type of major resection as well as the
approach to surgery, use of neoadjuvant radiotherapy19
and adjuvant chemotherapy.21 Significant work has also
Table 1 Continued
Data item Description of field content Format Source of information
4¼postoperative radiotherapy
5¼other radiotherapy
Adjuvant chemotherapy 0¼no 1¼ yes Number Derived by the UK Colorectal Cancer
Intelligence Hub from information in mul-
tiple datasets
Type of chemotherapy 1¼ single agent, 2¼ combination agent Number Derived by the UK Colorectal Cancer
Intelligence Hub from information in mul-
tiple datasets
Linkages Flags to indicate whether the person or
tumour links to other datasets available in
CORECT-R
Derived by the UK Colorectal Cancer
Intelligence Hub from information in mul-
tiple datasets
ICD, International Classification of Diseases; NCRAS, National Cancer Registration and Analysis Service; CORECT-R, COloRECTal cancer data Repository;
TNM, Cancer staging system (T ¼ Tumour, N ¼ Nodes, M ¼ Metastases); HES, Hospital Episodes Statistics; OPCS4, Classification of Interventions and
Procedures version 4; ACPGBI, Association of Coloproctologists of Great Britain and Ireland.
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Table 2 Variables in the National Anal Cancer Dataset within CORECT-R. Currently these relate to the English population, but
work is under way to expand to cover the UK
Data item Description of field content Format Source of information
Pseudonymized per-
son ID




Unique study specific identifier for each tumour Number Derived by the UK Colorectal Cancer
Intelligence Hub
Age Option to derive age information in a format
suitable for the research project needs. Can be
single age or summarized in age bands (e.g. 5-
year) and can could also include month and
year of birth
Number Cancer registration dataset
Sex 0¼not known, 1¼male, 2¼ female, 9¼not
specified
Number Cancer registration dataset
Ethnic group Option to group ethnicities (e.g. White/non-
White/unknown). Several methods of deriving
ethnicity information have been used previ-
ously and can be derived as per user
requirements
Text Derived by the UK Colorectal Cancer
Intelligence Hub from information




Option to include an appropriate indicator of so-
cioeconomic status such as the Index of
Multiple Deprivation
Number Derived by the UK Colorectal Cancer
Intelligence Hub from information
in multiple datasets
Vital status of the
patient
A ¼ alive, D ¼ dead, X ¼ exit posting Char(1) Cancer registration dataset
Days from diagnosis
to death
Time in days between specified anal cancer diag-
nosis and death or censoring
Number Derived by the UK Colorectal Cancer
Intelligence Hub from information
in the cancer registration dataset
Days from another
event to date of
death
Option to provide number of days from another
event to death (e.g. days from diagnosis to
death). Derived as per user requirements
Number Derived by the UK Colorectal Cancer
Intelligence Hub from information
in key events from different datasets
Cause of death Option to derive summary cause of death infor-
mation based on the causes of death listed on
death certificates or coded by former regional
registries. Derived as per user requirements
Text Cancer registration dataset
Place of death Option to derive place of death based on infor-
mation recorded on death certificates or from
Hospital Episode Statistics. Derived as per
user requirements
Cancer registration dataset
Diagnosis date Option to derive diagnosis date in a format suit-
able for the research project needs. This is
likely to be in the format MM/YYYY unless




event to date to
diagnosis
Option to provide number of days from another
event to diagnosis (e.g. days from birth to di-
agnosis). Derived as per user requirements
Number Derived by the UK Colorectal Cancer
Intelligence Hub from information
in multiple datasets
Basis of diagnosis of
the tumour
0¼death certificate, 1¼ clinical, diagnosis made
before death without (2-7), 2¼ clinical investi-
gation, 4¼ specific tumour markers,
5¼ cytology, 6¼histology of metastases,
7¼histology of primary tumour,
9¼unknown
Number Cancer registration dataset
Route to diagnosis 1¼GP referral, 2¼2-week wait pathway, 3 ¼
emergency presentation, 4¼other outpatient,
Number Cancer registration dataset
(Continued)
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Table 2 Continued
Data item Description of field content Format Source of information
5¼ screen detected, 6¼ inpatient elective,
7¼death certificate only, 9¼unknown
Site of neoplasm (4-
character code)
Valid 4-digit ICD-10 codes in the range C21 Char(4) Cancer registration dataset
Morphology The original 5-digit ICD03 morphology informa-
tion captured by NCRAS
Char(5) Cancer registration dataset
Morphology group A grouped morphology variable derived by
grouping the detailed morphology information
available in NCRAS to provide the more use-
able histology types. For many analyses it may
be appropriate to limit cases to exclude rare
morphological sub types with non-standard
treatment or unusual behaviour.
Number Derived by the UK Colorectal Cancer
Intelligence Hub from information
in the cancer registration dataset
Summary stage A summary stage that combines information
from the multiple staging variables available
in NCRAS to maximize the number of cases
with a stage classification
Number Cancer registration dataset
Staging information Option to derive staging information from any
of the data items available in the CORECT-R
tables (likely to be predominantly NCRAS
Tumour table). This can include individual
components of TNM or any other information
that can be reported alone or combined as
demanded by the research project. Derived as
per user requirements
Derived by the UK Colorectal Cancer
Intelligence Hub from information
in the cancer registration dataset
Comorbidity scores Option to access a number of different comor-
bidity scores (such as Charlson, Elixhauser,
C3) created as per user requirements. This
could include using a previously published ap-
plication of these scores or bespoke algorithms
as demanded by the research project
Number Derived by the UK Colorectal Cancer




1¼APE, 0¼no APE Char(1) Derived by the UK Colorectal Cancer
Intelligence Hub from information




Time in days between specified anal cancer diag-
nosis and APE
Number Derived by the UK Colorectal Cancer
Intelligence Hub from information
in the cancer registry and relevant
hospital discharge dataset
Surgical information Option to provide surgical treatment informa-
tion. Derived as per user requirements
Derived by the UK Colorectal Cancer




Option to provide radiotherapy treatment infor-
mation. Derived as per user requirements
Derived by the UK Colorectal Cancer




Option to provide chemotherapy treatment in-
formation. Derived as per user requirements
Derived by the UK Colorectal Cancer
Intelligence Hub from information
in multiple datasets
Linkages Flags to indicate whether the person or
tumour links to other datasets available in
CORECT-R
Derived by the UK Colorectal Cancer
Intelligence Hub from information
in multiple datasets
ICD, International Classification of Diseases; NCRAS, National Cancer Registration and Analysis Service; CORECT-R, COloRECTal cancer data Repository;
TNM, cancer staging system (T ¼ Tumour, N ¼ Nodes, M ¼Metastases); APE, abdominoperineal excision.
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been undertaken looking at the management of metastatic
disease.20 The Programme team regularly provide these
reports to Yorkshire’s multidisciplinary teams giving them
information on how their cases compare with those man-
aged by other teams in the region, as well as England as a
whole. Clinical engagement is then sought to try to under-
stand and explain why any variation exists which, in turn,
leads to initiatives aimed at minimizing it.
There are numerous other examples of how the data
within CORECT-R can be used and more details are avail-
able on the Hub’s website, alongside a summary of all the
projects currently under way, or completed, using the
resource.
Strengths and weaknesses
The main strength of CORECT-R is that it streamlines the
extremely resource-intensive processes that researchers go
through to access population-based datasets relevant to co-
lorectal cancer. Previously, many research and service
groups all worked in parallel to seek their own permissions
to obtain extracts of data. They then undertook bespoke
linkages and used different methods to analyse these data
and, in consequence, often obtained slightly different find-
ings.29 This results in significant duplication of effort and
resource, as well as confusion for those wishing to make
use of the resulting intelligence. In addition, multiple data
transfers increase the risk of data breaches that may
threaten patient confidentiality and public trust.
CORECT-R offers an alternative and more efficient route
to the data and this collaborative approach, in turn, enhan-
ces the abilities of the cancer intelligence community to
produce the evidence needed to drive improvements in co-
lorectal cancer care.
Although the collaborative approach of CORECT-R is
a strong model, it does pose challenges. These often arise
because the resource aims to align datasets owned by mul-
tiple different organizations who all have their own poli-
cies and procedures relating to data access and these
sometimes conflict. In addition, when different datasets
containing the same information for individuals (for exam-
ple date of diagnosis, type of surgery or site of tumour) are
aligned, they can disagree, and this leads to significant
challenges in quality-assuring the information. Again how-
ever, via the collaborative nature of the Hub and the trans-
parent data management and processing pathways it
adopts, these challenges can be overcome.
CORECT-R aims to contain detailed information about
all colorectal cancer patients in the UK and it is vital to re-
spect the interests of those people to whom these data per-
tain and, in a very real sense, belong. Another strength of
the UK Colorectal Cancer Intelligence Hub and its
CORECT-R resource is its involvement of patients and
the public. As a direct result, the concerns about the
security and use of patient data are fully appreciated by the
Hub team, and we have sought to design a system that
will minimize these risks and anxieties while also maximiz-
ing the benefit the analysis of such population data can
have. The Hub’s Patient-Public Group is extremely active
and involved in the management of CORECT-R and its
outputs.
Data resource access
Researchers who wish to make use of the CORECT-R re-
source should contact the UK Colorectal Cancer
Intelligence Hub team and discuss their requirements. The
application process will differ depending on the details of
the proposed project and the source of the data required.
The application process centres on the development of a
project protocol that describes the information required,
justifies its use and sets out the study objectives. The Hub
team will support the applicant through the process. For
more details, see [https://www.ndph.ox.ac.uk/corectr].
The Hub website also hosts information on the data
available within CORECT-R. The data catalogue contains
detailed information on the ‘research ready’ national colo-
rectal and anal cancer datasets. In addition, it also provides
information on all the individual component datasets
within CORECT-R and where to find more information
about their content.
Cancer Research UK, the funders of the resource, and
the UK Colorectal Cancer Intelligence Hub itself, are keen
to ensure that the data within CORECT-R are used for the
maximum benefit of colorectal cancer patients and, as
such, have resourced the project to enable free access to ac-
ademic researchers.
The publications arising from any projects that include
CORECT-R data have to acknowledge the resource and its
funding as well as the people who contribute data into the
resource, with the following attributions:
This project involves data that have been provided by,
or derived from, patients and collected by the NHS as
part of their care and support.
This work was supported by Cancer Research UK
(C23434/A23706), which underpinned data access via
the UK Colorectal Cancer Intelligence Hub.
Finally, CORECT-R contains many different datasets
and, if used in a particular project, the organizations who
have contributed data need to be acknowledged. Users will
be made aware of relevant attributions on a project-by-
project basis.
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